Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging

Circulation: Heart Failure

Volumn 9, Issue 1, 2016, Pages

  Bloom, Michelle W ^a   Hamo, Carine E ^a   Cardinale, Daniela ^b   Ky, Bonnie ^c   Nohria, Anju ^d   Baer, Lea ^a   Skopicki, Hal ^a   Lenihan, Daniel J ^e   Gheorghiade, Mihai ^f   Lyon, Alexander R ^g   Butler, Javed ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Anthracyclines; cardiomyopathies; cardiotoxicity; chemotherapy; heart failure; trastuzumab; ventricular dysfunction, left

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TROPONIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; DIASTOLIC DYSFUNCTION; DISEASE CLASSIFICATION; HEART DISEASE; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIATION INJURY; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SPECKLE TRACKING ECHOCARDIOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ADVERSE EFFECTS; BLOOD; CARDIOMYOPATHIES; CHEMICALLY INDUCED; COMORBIDITY; DIAGNOSTIC IMAGING; NEOPLASMS; NOMENCLATURE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RADIATION INJURIES; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CARDIOMYOPATHIES; COMORBIDITY; DIAGNOSTIC IMAGING; HEART FAILURE; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84955282878     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.115.002661     Document Type: Article

References (97)

1. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ; ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991-4008. doi: 10.1200/JCO.2007.10.9777.
2. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, Delaat C, Steinherz LJ, Zhao H. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-828. doi: 10.1200/JCO.2004.06.022.
3. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64. doi: 10.1186/bcr2901.
4. Rowinsky EK MW, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704-1712.
5. Sorrentino MF KJ, Eoderaro AE, Truesdell AG. 5-Fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19:453-458.
6. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084. doi: 10.1056/NEJM200004133421502.
7. NCI Dictionary of Cancer Terms. Definition of cardiotoxicity. http://www. cancer.gov/dictionaryCdrID=44004%3E. Accessed October 31, 2015
8. NCI. Common Terminology Criteria for Adverse Events (CTCAE); 2009.
9. FDA Drug Label for DOXIL-doxorubicin hydrochloride injection, suspension, liposomal. Available at: http://dailymed.nlm.nih.gov.ezproxy.hsclib. sunysb.edu/dailymed/drugInfo.cfmsetid=21d9c619-7e94-49e2-ac41-31e9ea96554a%3E. Accessed October 31, 2015.
10. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-1221.
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. doi: 10.1056/NEJMoa052306.
12. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283. doi: 10.1056/NEJMoa0910383.
13. Plana JC GM, Barac A, Ewer M, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-939.
14. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900-2902. doi: 10.1200/JCO.2005.05.827.
15. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910-3916. doi: 10.1200/JCO.2009.27.3615.
16. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981-1988. doi: 10.1161/CIRCULATIONAHA.114.013777.
17. Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med. 1974;80:249-259.
18. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466-468.
19. Vejpongsa P, Yeh ET. Topoisomerase 2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95:45-52. doi: 10.1038/clpt.2013.201.
20. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839-8846. doi: 10.1158/0008-5472.CAN-07-1649.
21. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144:3-15. doi: 10.1016/j. ijcard.2010.03.003.
22. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, Villain E, de Vathaire F, Sidi D, Hartmann O. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37-44. doi: 10.1038/sj.bjc.6601904.
23. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7:214-20.
24. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
25. Gershwin ME, Goetzl EJ, Steinberg AD. Cyclophosphamide: use in practice. Ann Intern Med. 1974;80:531-540.
26. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9:1215-1223.
27. Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31-36.
28. Field JJ, Kanakkanthara A, Miller JH. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg Med Chem. 2014;22:5050-5059. doi: 10.1016/j.bmc.2014.02.035.
29. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one-or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002;8:3360-3368.
30. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P and Bonadonna G. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11:8715-21.
31. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN; National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103-2111. doi: 10.1056/NEJMoa054504.
32. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21:309-318. doi: 10.1016/S0149-2918(00)88288-0.
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. doi: 10.1056/NEJMoa052306.
34. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293-1305. doi: 10.1093/jnci/djs317.
35. Network NCC. Breast Cancer Version 3.2015; 2015.
36. Valachis A, Nearchou A, Lind P, Mauri D. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res Treat. 2012;135:655-662. doi: 10.1007/s10549-012-2189-z.
37. Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, Citron ML, Campone M, Xu N, Smitt M, Gianni L. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo) adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol. 2015;33:1136-1142. doi: 10.1200/JCO.2014.58.7782.
38. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280:C1358-C1366.
39. Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. J Appl Toxicol. 2012;32:945-951. doi: 10.1002/jat.2813.
40. Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Curr Treat Options Cardiovasc Med. 2014;16:335. doi: 10.1007/s11936-014-0335-0.
41. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. doi: 10.1056/NEJMoa065044.
42. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol. 2011;29:3450-3456. doi: 10.1200/JCO.2010.34.4309.
43. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1:72-78. doi: 10.1016/j. jchf.2012.09.001.
44. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29:632-638. doi: 10.1200/JCO.2010.31.9129.
45. Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012;20:184-188. doi: 10.1097/CRD.0b013e3182431c23.
46. van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007-1017. doi: 10.1001/jamainternmed.2015.1180.
47. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987-998. doi: 10.1056/NEJMoa1209825.
48. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14-25. doi: 10.1093/jnci/djp440.
49. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S. Anthracyclinerelated cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol. 2012;30:1415-1421. doi: 10.1200/JCO.2011.34.8987.
50. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874-1880. doi: 10.1136/heartjnl-2015-307848.
51. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010;53:94-104. doi: 10.1016/j.pcad.2010.05.006.
52. Valachis A, Nilsson C. Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press). 2015;7:21-35. doi: 10.2147/BCTT.S47227.
53. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89:1287-1306. doi: 10.1016/j. mayocp.2014.05.013.
54. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. doi: 10.1056/NEJMoa052122.
55. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 2008;107:443-450. doi: 10.1007/s10549-007-9803-5.
56. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3:e000472. doi: 10.1161/JAHA.113.000472.
57. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-2754. doi: 10.1161/01.CIR.0000130926.51766.CC.
58. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol. 2013;40:186-198. doi: 10.1053/j.seminoncol.2013.01.008.
59. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596-603. doi: 10.1161/CIRCIMAGING.112.973321.
60. Ederhy S, Massard C, Dufaitre G, Balheda R, Meuleman C, Rocca CG, Izzedine H, Cohen A, Soria JC. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs. 2012;30:611-615. doi: 10.1007/s10637-010-9546-8.
61. Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, Di Mauro M, Ficorella C, Penco M. Serial measurements of NTproBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 2011;105:1663-1668. doi: 10.1038/bjc.2011.439.
62. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin MA, Sallan SE. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042-1049. doi: 10.1200/JCO.2010.30.3404.
63. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. Highsensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumabinduced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134:291-298. doi: 10.1007/s10549-012-2039-z.
64. Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA. Highsensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumabinduced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2012;134:291-298. doi: 10.1007/s10549-012-2039-z.
65. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809-816. doi: 10.1016/j.jacc.2013.10.061.
66. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, Passeri J, Cohen V, Banchs J, Martin RP, Gerszten RE, Scherrer-Crosbie M, Ky B. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015;61:1164-1172. doi: 10.1373/clinchem.2015.241232.
67. Skovgaard D, Hasbak P, Kjaer A. BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS One. 2014;9:e96736. doi: 10.1371/journal. pone.0096736.
68. Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17:3490-3499. doi: 10.1158/1078-0432.CCR-10-1359.
69. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, Pourier MS, Feuth T, Bökkerink JP, Hoogerbrugge PM, Kapusta L. Abnormal NTpro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer. 2009;52:631-636. doi: 10.1002/pbc.21913.
70. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97:318-326. doi: 10.1007/s00392-007-0633-6.
71. Jingu K, Nemoto K, Kaneta T, Oikawa M, Ogawa Y, Ariga H, Takeda K, Sakayauchi T, Fujimoto K, Narazaki K, Takai Y, Nakata E, Fukuda H, Takahashi S, Yamada S. Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys. 2007;69:1417-1423. doi: 10.1016/j.ijrobp.2007.05.054.
72. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, Martinelli G, Cipolla CM. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248-252.
73. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517-522.
74. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108:1146-1162. doi: 10.1161/01. CIR.0000073597.57414.A9.
75. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, Burns PN, Castello R, Coon PD, Hagen ME, Jollis JG, Kimball TR, Kitzman DW, Kronzon I, Labovitz AJ, Lang RM, Mathew J, Moir WS, Nagueh SF, Pearlman AS, Perez JE, Porter TR, Rosenbloom J, Strachan GM, Thanigaraj S, Wei K, Woo A, Yu EH, Zoghbi WA; American Society of Echocardiography. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr. 2008;21:1179-1201; quiz 1281. doi: 10.1016/j.echo.2008.09.009.
76. Kongbundansuk S, Hundley WG. Noninvasive imaging of cardiovascular injury related to the treatment of cancer. JACC Cardiovasc Imaging. 2014;7:824-838. doi: 10.1016/j.jcmg.2014.06.007.
77. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J. 2009;30:98-106. doi: 10.1093/eurheartj/ehn484.
78. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovi ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77-84. doi: 10.1016/j.jacc.2012.09.035.
79. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063-1093. doi: 10.1093/ehjci/jeu192.
80. Oreto L, Todaro MC, Umland MM, Kramer C, Qamar R, Carerj S, Khandheria BK, Paterick TE. Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know J Am Soc Echocardiogr. 2012;25:1141-1152. doi: 10.1016/j.echo.2012.09.001.
81. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62-69.
82. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, Blaise AM, Elaerts J, Nazeyrollas P. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006;7:141-146. doi: 10.1016/j. euje.2005.04.009.
83. Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, Byth K, Stuart K, Clarke JL, Thomas L. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. Eur J Cancer. 2013;49:3396-3403. doi: 10.1016/j.ejca.2013.06.046.
84. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493-498. doi: 10.1016/j.echo.2013.02.008.
85. Motoki H, Koyama J, Nakazawa H, Aizawa K, Kasai H, Izawa A, Tomita T, Miyashita Y, Kumazaki S, Takahashi M, Ikeda U. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13:95-103. doi: 10.1093/ejechocard/jer172.
86. Tanindi A, Demirci U, Tacoy G, Buyukberber S, Alsancak Y, Coskun U, Yalcin R, Benekli M. Assessment of right ventricular functions during cancer chemotherapy. Eur J Echocardiogr. 2011;12:834-840. doi: 10.1093/ejechocard/jer142.
87. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978;62:857-864.
88. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-939. doi: 10.1016/j.echo.2014.07.012.
89. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30:2876-2884. doi: 10.1200/JCO.2011.40.3584.
90. Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6:1080-1091. doi: 10.1161/CIRCIMAGING.113.000899.
91. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson. 2008;10:5. doi: 10.1186/1532-429X-10-5.
92. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol. 2012;110:1679-1686. doi: 10.1016/j.amjcard.2012.07.040.
93. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19:377-388. doi: 10.1007/s12350-012-9512-2.
94. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402-415. doi: 10.2967/jnumed.112.105353.
95. Nappi C, El Fakhri G. State of the art in cardiac hybrid technology: PET/MR. Curr Cardiovasc Imaging Rep. 2013;6:338-345. doi: 10.1007/s12410-013-9213-5.
96. Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014;3:e000665. doi: 10.1161/JAHA.113.000665.
97. Catana C, Guimaraes AR, Rosen BR. PET and MR imaging: the odd couple or a match made in heaven J Nucl Med. 2013;54:815-824. doi: 10.2967/jnumed.112.112771.